TREVI THERAPEUTICS INC (TRVI) Stock Analyst Ratings
USA - NASDAQ:TRVI - US89532M1018 - Common Stock
10.58 USD
+0.05 (+0.47%)
10.58 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 86% to TRVI. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 19.97. This target is 88.8% above the current price.
TRVI was analyzed by 18 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about TRVI.
In the previous month the buy percentage consensus was at a similar level.
TRVI was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-21 | Morgan Stanley | Initiate | Overweight |
| 2025-08-08 | Needham | Maintains | Buy -> Buy |
| 2025-08-08 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2025-07-01 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-06-02 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-05-28 | HC Wainwright & Co. | Initiate | Buy |
| 2025-05-20 | Needham | Reiterate | Buy -> Buy |
| 2025-04-08 | Needham | Reiterate | Buy -> Buy |
| 2025-03-19 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-19 | Needham | Maintains | Buy -> Buy |
| 2025-03-19 | B. Riley Securities | Reiterate | Buy -> Buy |
| 2025-03-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-11 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-03-10 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-10 | Needham | Maintains | Buy -> Buy |
| 2025-03-10 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2025-03-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-07 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-02-24 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-08 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-12-16 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-12-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-12 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-12-12 | Needham | Reiterate | Buy -> Buy |
| 2024-12-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-12-04 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-12-04 | Needham | Reiterate | Buy -> Buy |
| 2024-12-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-08 | Needham | Reiterate | Buy -> Buy |
| 2024-11-07 | EF Hutton | Maintains | Buy -> Buy |
TREVI THERAPEUTICS INC / TRVI FAQ
What do analysts expect the price target to be for TREVI THERAPEUTICS INC (TRVI)?
18 analysts have analysed TRVI and the average price target is 19.98 USD. This implies a price increase of 88.8% is expected in the next year compared to the current price of 10.58.
What is the consensus rating for TREVI THERAPEUTICS INC (TRVI) stock?
The consensus rating for TREVI THERAPEUTICS INC (TRVI) is 85.5556 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed TREVI THERAPEUTICS INC (TRVI)?
The number of analysts covering TREVI THERAPEUTICS INC (TRVI) is 18.